Table 1.
Baseline demographics and clinical characteristics of the patients
| Characteristics | TwHF (n=58) | Acitretin (n=57) | Total (n=115) |
|---|---|---|---|
| Age, years (mean±SD) | 42.0 ± 12.0 | 40.2 ± 12.4 | 41.1 ± 12.2 |
| Range, years | 22–65 | 20–65 | 20–65 |
| Sex, male (n (%)) | 38 (65.5) | 43 (75.4) | 81 (70.4) |
| BMI, kg/m2 (mean± SD) | 24.6 ± 3.4 | 24.3 ± 4.3 | 24.5 ± 3.8 |
| Duration of psoriasis, years (mean±SD) | 11.8 ± 9.1 | 13.8 ± 11.7 | 12.8 ± 10.5 |
| Range, years | 0.1–34 | 0.1–58 | 0.1–58 |
| PASI (mean±SD) | 23.8 ± 16.3 | 23.2 ± 13.8 | 23.5 ± 15.0 |
| Prior acitretin exposure, n (%) | 8 (13.8) | 3 (5.3) | 11 (9.6) |
| Prior tripterygium exposure, n (%) | 9 (15.5) | 2 (3.5) | 11 (9.6) |
| Prior systemic steroids exposure, n (%) | 3 (5.2) | 2 (3.5) | 5 (4.3) |
SD: Standard deviation; TwHF: Tripterygium wilfordii Hook F; BMI: Body mass index; PASI: Psoriasis area severity index.